The launch of a COVID-19 diagnostic laboratory in an oncology hospital – a review of guidelines and the laboratory team’s own experiences
Abstract
The first case of the coronavirus SARS-CoV-2 infection was confirmed in December 2019 in Wuhan, China, from whence the virus spread across the world within several weeks. Due to the alarming level of infections, the World Health Organisation (WHO) announced a SARS-CoV-2 pandemic on 12 March. This dynamic and unprecedented epidemiological situation created an urgent need to carry out SARS-CoV-2 tests in individuals meeting the criteria defined for COVID-19 suspect cases. According to the current WHO recommendations, active SARS-CoV-2 infection diagnostics is based on molecular method using a real-time reverse transcription – polymerase chain reaction (real-time RT-PCR). Highly specific and sensitive, this method makes it possible to detect even a small amount of RNA particles of the virus in the tested sample. Undoubtedly, the launch of new COVID laboratories and the implementation of adequate procedures increases the effectiveness of activities aimed at directly combatting the SARS-CoV-2 pandemic. The population of oncological patients is particularly exposed to the risk of complications and death resulting from the SARS-CoV-2 infection; therefore it is essential to ensure them the possibility of quick testing for COVID-19. This article presents the authors’ own experiences as well as technical and formal issues related to the launching of a SARS-CoV-2 laboratory.
Keywords: COVID-19SARS-CoV-2diagnosticsreal-time RT-PCR
References
- Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. Interim guidance, 2 March 2020, WHO.
- Laboratory biosafety guidance related to coronavirus disease 2019 (COVID-19) Interim guidance, 12 February 2020, WHO.
- Katarzyna Dzierżanowska-Fangrat, Konsultant krajowy w dziedzinie mikrobiologii lekarskiej, Zasady pobierania i transportu materiału do badań metodami molekularnymi RT PCR w kierunku SARS-CoV-2, aktualizacja 14.04.2020. https://kidl.org.pl/get-file/2671 (13.05.2020).
- Rekomendacje NIZP-PZH w zakresie diagnostyki molekularnej SARS-CoV-2 Warszawa 24.04.2020. https://www.pzh.gov.pl/wp-content/uploads/2020/04/Rekomendacje-w-zakresie-diagnostyki-molekularnej-SARS-CoV-2.pdf (13.05.2020).
- Rekomendacje NIZP-PZH: Wymagania dotyczące pobrania i transportu materiału do badań metodą RT-PCR w kierunku zakażeń układu oddechowego powodowanych przez koronawirusy (SARS; MERS; SARS-CoV-2 – COVID-19). Warszawa 29.02.2020. https://www.pzh.gov.pl/wp-content/uploads/2020/02/Wymagania-dotycz%C4%85ce-materia%C5%82u-do-bada%C5%84-COVID-19-29.02.2020.pdf (13.05.2020).
- CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19).
- Zalecenia i rekomendacje Polskiego Towarzystwa Onkologicznego dla pacjentów onkologicznych w związku z epidemią wirusa SARS-CoV-2 08.042020.
- Leczenie systemowe pacjentów z rozpoznaniem choroby nowotworowej w kontekście pandemii SARS-CoV-2 — stanowisko Polskiego Towarzystwa Onkologii Klinicznej 20.03.2020.
- Guan WJ, Ni ZY, Hu Yu, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–1720.
- Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy. http://onkologia.org.pl/raporty/ (13.05.2020).
- Matheeussen V, Corman VM, Donoso Mantke O, et al. RECOVER project and collaborating networks. International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic, April/May 2020. Euro Surveill. 2020; 25(27).
- Rekomendacje dotyczące walidacji badań molekularnych w kierunku SARS-CoV2 w sieci laboratoriów COVID, Ministerstwo Zdrowia 21.04.2020.